DBV Technologies (NASDAQ:DBVT) Stock Rating Lowered by Wall Street Zen

DBV Technologies (NASDAQ:DBVT) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other brokerages have also issued reports on DBVT. HC Wainwright set a $40.00 target price on DBV Technologies in a research note on Thursday, December 18th. Guggenheim reissued a “buy” rating and issued a $51.00 price objective (up from $35.00) on shares of DBV Technologies in a report on Wednesday, December 17th. Citizens Jmp lifted their target price on DBV Technologies from $21.00 to $45.00 and gave the stock a “market outperform” rating in a report on Wednesday, December 17th. Cantor Fitzgerald set a $48.00 target price on DBV Technologies in a research report on Wednesday, December 17th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of DBV Technologies in a report on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, DBV Technologies has a consensus rating of “Moderate Buy” and a consensus target price of $35.38.

DBV Technologies Trading Down 5.9%

Shares of DBV Technologies stock opened at $21.61 on Friday. The firm’s 50 day simple moving average is $18.47 and its two-hundred day simple moving average is $13.96. The firm has a market capitalization of $867.86 million, a price-to-earnings ratio of -4.18 and a beta of -1.17. DBV Technologies has a 12-month low of $3.80 and a 12-month high of $26.18.

Insider Activity

In related news, major shareholder Bpifrance Epic sold 2,076,990 shares of the stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $4.85, for a total transaction of $10,073,401.50. Following the sale, the insider directly owned 8,595,472 shares of the company’s stock, valued at approximately $41,688,039.20. This represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 1.44% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On DBV Technologies

A number of hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC lifted its position in shares of DBV Technologies by 38.4% during the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after buying an additional 744 shares in the last quarter. New York State Common Retirement Fund acquired a new stake in shares of DBV Technologies in the 3rd quarter worth $34,000. Two Sigma Investments LP acquired a new stake in DBV Technologies during the third quarter worth about $167,000. Citadel Advisors LLC acquired a new position in DBV Technologies in the 3rd quarter valued at about $220,000. Finally, DLD Asset Management LP purchased a new stake in shares of DBV Technologies in the 3rd quarter valued at approximately $250,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.